Point-of-Care Assays Could Be Useful for Therapeutic Drug Monitoring of IBD Patients in a Proactive Strategy with Adalimumab

The objective of the study was to evaluate whether Point-of-Care (POC) assays are equivalent to ELISAs for measuring residual trough levels of adalimumab (ADA) in a cohort of Inflammatory Bowel Disease (IBD) patients. ADA trough levels obtained by POC assays were used to optimize patients in daily c...

Descripción completa

Detalles Bibliográficos
Autores principales: Cherry, Mohamad, Dutzer, Dominique, Nasser, Yara, Berger, Anne-Emmanuelle, Roblin, Xavier, Paul, Stephane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565289/
https://www.ncbi.nlm.nih.gov/pubmed/32854232
http://dx.doi.org/10.3390/jcm9092739

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565289/
https://www.ncbi.nlm.nih.gov/pubmed/32854232
http://dx.doi.org/10.3390/jcm9092739

Ejemplares similares